ABSTRACT
Mammalian cells integrate different types of stimuli that govern their fate. These stimuli encompass biochemical as well as biomechanical cues (shear, tensile, and compressive stresses) that are usually studied separately. The phosphatidylinositol 3-kinase (PI3K) enzymes, producing signaling phosphoinositides at plasma and intracellular membranes, are key in intracellular signaling and vesicular trafficking pathways. Recent evidence in cancer research demonstrates that these enzymes are essential in mechanotransduction. Despite this, the importance of the integration of biomechanical cues and PI3K-driven biochemical signals is underestimated. In this opinion article, we make the hypothesis that modeling of biomechanical cues is critical to understand PI3K oncogenicity. We also identify known/missing knowledge in terms of isoform specificity and molecular pathways of activation, knowledge that is needed for clinical applications.
Subject(s)
Mechanotransduction, Cellular , Phosphatidylinositol 3-Kinase , Animals , Mammals , Mechanotransduction, Cellular/physiology , Phosphatidylinositol 3-Kinase/metabolism , Phosphatidylinositol 3-Kinases/metabolism , Signal Transduction/physiologyABSTRACT
Pancreatic ductal adenocarcinoma PDAC is considered as one of the less immunogenic solid tumor types. Pancreatic tumors are also known to present a high autophagy flux which supports tumor progression. Autophagy was recently described as a tumor-intrinsic immune escape process during tumor development by sequestration of Major Histocompatibility Complex class I (MHC-I) inside the PDAC cells. We comment this discovery and discuss the implications on how to limit immune escape in patients and how to improve immunotherapy efficiency. Currently, pancreatic adenocarcinoma is the most frequent pancreatic cancer with a poor prognosis, an important lethality, and a 5-year overall survival less than 5%. The development of some therapeutic solutions like targeted therapies are promising [1]. However, it is still important to understand this morbid pathology to improve the treatment, because PDAC is predicted to be the second leading cause of death in Western countries [2].
Subject(s)
Adenocarcinoma , Carcinoma, Pancreatic Ductal , Pancreatic Neoplasms , Autophagy , Carcinoma, Pancreatic Ductal/therapy , Humans , Immunotherapy , Pancreatic Neoplasms/therapyABSTRACT
Phosphoinositide 3-kinases PI3Ks are major drug targets in oncology. Their role is far from being completely understood in pancreatic ductal adenocarcinoma. Pancreatic cancer is a dismal disease with limited therapeutic options except for surgery. We highlight here two elegant works demonstrating the role of PI3Kγ in cancer-associated macrophages applied in particular to pancreatic tumors. These data open new avenues for the use of PI3K-targetting drugs in cancer as anti-stroma therapies. Amongst the classI PI3K isoforms, PI3Kγ and PI3Kδ, are highly expressed in immune cells. Isoform-specific or pan-class I PI3K inhibitors which target all classI PI3Ks could be used as a targeted therapy towards cancer cell signaling but also as immunotherapies. Research on immunoregulation of human pancreatic cancer by the other ubiquitous α- or ß-isoforms of PI3K needs to be performed.
Subject(s)
Adenocarcinoma/drug therapy , Adenocarcinoma/immunology , Class Ib Phosphatidylinositol 3-Kinase/immunology , Macrophages/immunology , Pancreatic Neoplasms/drug therapy , Pancreatic Neoplasms/immunology , Phosphoinositide-3 Kinase Inhibitors , Animals , Humans , Mice , Protein Isoforms/antagonists & inhibitorsSubject(s)
Carcinoma, Pancreatic Ductal/immunology , Hemidesmosomes/immunology , Pancreatic Neoplasms/immunology , Animals , Carcinoma, Pancreatic Ductal/pathology , Disease Models, Animal , Hemidesmosomes/metabolism , Hemidesmosomes/pathology , Humans , Mice , Neoplasm Invasiveness , Pancreatic Neoplasms/metabolism , Pancreatic Neoplasms/pathologyABSTRACT
Somatostatin is a multifunctional hormone that modulates cell proliferation, differentiation and apoptosis. Mechanisms for somatostatin-induced apoptosis are at present mostly unsolved. Therefore, we investigated whether somatostatin receptor subtype 2 (sst2) induces apoptosis in the nontransformed murine fibroblastic NIH3T3 cells. Somatostatin receptor subtype 2 expression induced an executioner caspase-mediated apoptosis through a tyrosine phosphatase SHP-1 (Src homology domain phosphatase-1)-dependent stimulation of nuclear factor kappa B (NF-kappaB) activity and subsequent inhibition of the mitogen-activated protein kinase JNK. Tumor necrosis factor alpha (TNFalpha) stimulated both NF-kappaB and c-Jun NH2-terminal kinase (JNK) activities, which had opposite action on cell survival. Importantly, sst2 sensitized NIH3T3 cells to TNFalpha-induced apoptosis by (1) upregulating TNFalpha receptor protein expression, and sensitizing to TNFalpha-induced caspase-8 activation; (2) enhancing TNFalpha-mediated activation of NF-kappaB, resulting in JNK inhibition and subsequent executioner caspase activation and cell death. We have here unraveled a novel signaling mechanism for a G protein-coupled receptor, which directly triggers apoptosis and crosstalks with a death receptor to enhance death ligand-induced apoptosis.
Subject(s)
Apoptosis , JNK Mitogen-Activated Protein Kinases/metabolism , NF-kappa B/metabolism , Receptors, Somatostatin/metabolism , Receptors, Tumor Necrosis Factor, Type I/metabolism , Somatostatin/metabolism , Animals , Apoptosis/drug effects , Caspases/metabolism , Enzyme Activation/drug effects , Gene Expression Regulation/drug effects , Humans , JNK Mitogen-Activated Protein Kinases/antagonists & inhibitors , Mice , Models, Biological , Molecular Mimicry/drug effects , NIH 3T3 Cells , Phosphorylation/drug effects , Protein Phosphatase 1 , Protein Tyrosine Phosphatase, Non-Receptor Type 6/metabolism , RNA, Messenger/genetics , RNA, Messenger/metabolism , Receptors, Tumor Necrosis Factor, Type I/genetics , Signal Transduction/drug effects , Transfection , Tumor Necrosis Factor-alpha/genetics , Tumor Necrosis Factor-alpha/pharmacologyABSTRACT
Since its discovery three decades ago as an inhibitor of GH release from the pituitary gland, somatostatin has attracted much attention because of its functional role in the regulation of a wide variety of physiological functions in the brain, pituitary, pancreas, gastrointestinal tract, adrenals, thyroid, kidney and immune system. Its actions include inhibition of endocrine and exocrine secretions, modulation of neurotransmission, motor and cognitive functions, inhibition of intestinal motility, absorption of nutrients and ions and vascular contractility. In addition, the peptide controls the proliferation of normal and tumor cells. Its action is mediated by a family of G protein-coupled receptors [somatostatin receptor (SSTR)1-SSTR5] that are widely distributed in normal and cancer cells. Direct antitumor activities, mediated through SSTR expressed in tumor cells, include blockade of autocrine/paracrine growth-promoting hormone and growth factor production, inhibition of growth factor-mediated mitogenic signals and induction of apoptosis. Indirect antitumor effects include inhibition of growth-promoting hormone and growth factor secretion, and antiangiogenic actions. Many human tumors express more than one SSTR subtype, with SSTR2 being predominant. These receptors represent the molecular basis for the clinical use of somatostatin analogs in the treatment of endocrine tumors and their in vivo localization. This review covers the present knowledge in SSTR biology and signaling.